Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Sugarbud chart: Target 0.12 on the breakout, an easy triple.

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson Aug 19, 2021 12:13pm

93 Views

Post# 33730715

RE:Sugarbud chart: Target 0.12 on the breakout, an easy triple.

Yes your right but forgot to add Bashers who bash to get people to sell so others can get cheaper shares, Like people like yourself with a 0 beside there name!!

Sugarbowls wrote: This room is full of paid pumpers. The ones that post here all day with a reputation of 1000 or more are paid to be here, looks at their posting history, this place is riddled with employees and paid pumping.

Guess all that pumping ain't doing a thing!

See you at 0.065 !